Treatment with Obinutuzumab Plus Venetoclax Reshapes the TRB Repertoire of CLL Patients

Overview

Journal Blood Cancer J

Date 2025 Jan 6

PMID 39762207

Authors

Paul J Hengeveld

Joyce Schilperoord-Vermeulen

P Martijn Kolijn

Julie M N Dubois

Peter E Westerweel

Sabina Kersting

Arnon P Kater

Mark-David Levin

Anton W Langerak

Affiliations

Soon will be listed here.

References

Siddiqi T, Soumerai J, Dorritie K, Stephens D, Riedell P, Arnason J . Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2021; 139(12):1794-1806. PMC: 10652916. DOI: 10.1182/blood.2021011895. View

Vardi A, Agathangelidis A, Stalika E, Karypidou M, Siorenta A, Anagnostopoulos A . Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015; 22(1):167-74. DOI: 10.1158/1078-0432.CCR-14-3017. View

Vardi A, Vlachonikola E, Karypidou M, Stalika E, Bikos V, Gemenetzi K . Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. Leukemia. 2016; 31(7):1555-1561. DOI: 10.1038/leu.2016.362. View

Vardi A, Vlachonikola E, Papazoglou D, Psomopoulos F, Kotta K, Ioannou N . T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. Clin Cancer Res. 2020; 26(18):4958-4969. DOI: 10.1158/1078-0432.CCR-19-3827. View

Yin Q, Sivina M, Robins H, Yusko E, Vignali M, OBrien S . Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017; 198(4):1740-1747. PMC: 5296363. DOI: 10.4049/jimmunol.1601190. View

Long M, Beckwith K, Do P, Mundy B, Gordon A, Lehman A . Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017; 127(8):3052-3064. PMC: 5531425. DOI: 10.1172/JCI89756. View

Papazoglou D, Wang X, Shanafelt T, Lesnick C, Ioannou N, De Rossi G . Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 2023; 143(1):57-63. PMC: 10797553. DOI: 10.1182/blood.2023020554. View

Kersting S, Dubois J, Nasserinejad K, Dobber J, Mellink C, van der Kevie-Kersemaekers A . Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol. 2022; 9(3):e190-e199. DOI: 10.1016/S2352-3026(22)00034-5. View

Rovida A, Maccalli C, Scarfo L, Dellabona P, Stamatopoulos K, Ghia P . Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020; 27(3):729-739. DOI: 10.1158/1078-0432.CCR-20-1632. View

10.

Hengeveld P, Schilperoord-Vermeulen J, van der Klift M, Dubois J, Kolijn P, Kavelaars F . Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia. Blood Cancer J. 2023; 13(1):102. PMC: 10317999. DOI: 10.1038/s41408-023-00870-2. View

11.

Zippelius A, Pittet M, Batard P, Rufer N, De Smedt M, Guillaume P . Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med. 2002; 195(4):485-94. PMC: 2193620. DOI: 10.1084/jem.20011658. View

12.

Gong S, Osei E, Kaplan D, Chen Y, Meyerson H . CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2015; 8(2):1613-21. PMC: 4396245. View

13.

Hansch L, Peipp M, Mastall M, Villars D, Myburgh R, Silginer M . Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma. Neuro Oncol. 2023; 25(11):2001-2014. PMC: 10628943. DOI: 10.1093/neuonc/noad108. View